Market Intelligence, Clinical Progress, and High-Purity Reagents for Multidrug Resistance Reversal & ADC Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MRP1/ABCC1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MRP1/ABCC1 Full-Length Membrane Protein (Nanodisc) High purity (>90%), Endotoxin <1EU/ug. Sequence Verified. Native conformation for ATPase assays. |
View MRP1 Products |
| Gene Delivery | MRP1/ABCC1 Lentivirus Premade Particles Full-length ORF for stable cell lines. High titer (>10^8 TU/ml), HEK293 expression system. |
View MRP1 Products |
| Benchmark Ab | Anti-MRP1 (Clone QCRL-3 Biosimilar) Recombinant positive control for Western Blot and IHC validation. |
View MRP1 Products |
| Validator | MRP1/ABCC1 siRNA Set For knockdown verification and specificity controls in efflux assays. |
View MRP1 Products |
| Related Target A | ABCB1 (P-glycoprotein) Critical paralog for selectivity counter-screening in multidrug resistance assays. |
View ABCB1 Products |
| Related Target B | ABCG2 (BCRP) Key ABC transporter for cross-reactivity profiling and functional selectivity panels. |
View ABCG2 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Functional Efflux Activity Evaluation | Lentivirus-mediated stable cell lines expressing full-length MRP1. Sequence verified, >95% transduction efficiency. Preserved vanadate-sensitive ATPase activity. |
| Cross-species Preclinical Toxicology | Human/Mouse/Cyno ortholog lentivirus available. Native glycosylation pattern maintained in HEK293 expression system. |
| Selectivity vs Other ABC Transporters | Parallel cell lines expressing ABCB1, ABCG2, and ABCC2 available for counter-screening. Isogenic background (HEK293). |
| False Positives in Screening | Validated siRNA included for specificity checks (reversal of calcein-AM efflux phenotype upon knockdown). |
Live MRP1/ABCC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The landscape for MRP1/ABCC1 modulation is shifting from broad-spectrum MDR reversal agents toward precision combination strategies. As ADC payloads and topoisomerase inhibitors face clinical limitation due to efflux-mediated resistance, the demand for isoform-selective inhibitors and predictive biomarker assays is intensifying. The next wave of R&D focuses on substrate-specific efflux blockade and CRISPR-based transcriptional repression to overcome chemoresistance in solid tumors. First-generation therapies historically struggled with dose-limiting toxicities, prompting a shift toward precise allosteric modulation and combination therapies (e.g., ADCs with specialized payloads).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Tekmira, academic consortia; Academic/Biotech Consortiums | Drug-resistant NSCLC, Breast Cancer, Refractory Solid Tumors | ATPase Assay (Need purified NBD domains >95% purity); Efflux Inhibition Assay (Need stable cell lines via Lentivirus) |
| ADC Payload Engineering | Daiichi Sankyo, Seagen | Solid Tumors (avoiding MRP1 substrates) | Efflux Evaluation (Need stable MRP1-overexpressing cell lines) |
| RNAi / Antisense | Emerging Biotechs | Lung Cancer (SCLC/NSCLC) | Gene Knockdown Validation (Need Sequence Verified ORFs) |
| Combination Therapy | Novartis, Pfizer | Refractory Leukemia, Chemo-resistant Cancers | Cross-reactivity Panel (Need ABCB1/ABCG2 comparator cell lines) |